Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. (PLRX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PLRX · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
4
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Pliant Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
PLRX insider buying and selling by quarter
PLRX insider selling · PLRX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · PLRX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
PLRX executive sell shares · PLRX board member insider trading · PLRX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jan 20, 2026 | Cummings Keith Lamont CFO | Sale | 24,002 | $31K | Form 4 |
| Jan 20, 2026 | Cheung Lily Chief Human Resource Officer | Sale | 7,534 | $10K | Form 4 |
| Jan 20, 2026 | Coulie Bernard President and CEO · Director | Sale | 89,375 | $114K | Form 4 |
| Jan 20, 2026 | Kuo Minnie COO | Sale | 6,917 | $9K | Form 4 |
| Jan 23, 2025 | Cheung Lily Chief Human Resource Officer | Award | 25,875 | — | Form 4 |
| Jan 23, 2025 | Ouimette Mike General Counsel & Corp. Sec'y | Award | 35,000 | — | Form 4 |
| Jan 23, 2025 | Hull Hans Chief Business Officer | Award | 40,150 | — | Form 4 |
| Jan 23, 2025 | Lefebvre Eric Chief Medical Officer | Award | 45,650 | — | Form 4 |
| Jan 23, 2025 | Cummings Keith Lamont CFO | Award | 56,650 | — | Form 4 |
| Jan 23, 2025 | Coulie Bernard President and CEO · Director | Award | 162,500 | — | Form 4 |
| Jan 17, 2025 | Coulie Bernard President and CEO · Director | Sale | 52,419 | $587K | Form 4 |
| Jan 17, 2025 | Cummings Keith Lamont CFO | Sale | 20,148 | $226K | Form 4 |
| Jan 17, 2025 | Hull Hans Chief Business Officer | Sale | 15,936 | $179K | Form 4 |
| Jan 17, 2025 | Lefebvre Eric Chief Medical Officer | Sale | 18,478 | $207K | Form 4 |
| Jan 17, 2025 | Cheung Lily Chief Human Resource Officer | Sale | 3,740 | $42K | Form 4 |
| Jan 17, 2025 | Ouimette Mike General Counsel & Corp. Sec'y | Sale | 13,270 | $149K | Form 4 |
| Jan 22, 2025 | Ouimette Mike General Counsel & Corp. Sec'y | Sale | 10,230 | $112K | Form 4 |
| Jul 10, 2024 | Lefebvre Eric Chief Medical Officer | Sale | 12,319 | $142K | Form 4 |
| Jul 10, 2024 | Hull Hans Chief Business Officer | Sale | 9,900 | $114K | Form 4 |
| Jul 10, 2024 | Cummings Keith Lamont CFO | Sale | 10,911 | $126K | Form 4 |
| Jul 10, 2024 | Coulie Bernard President and CEO · Director | Sale | 38,710 | $447K | Form 4 |
| Jul 10, 2024 | Ouimette Mike General Counsel & Corp. Sec'y | Sale | 7,656 | $89K | Form 4 |
| Jul 9, 2024 | Lefebvre Eric Chief Medical Officer | Award | 24,063 | — | Form 4 |
| Jul 9, 2024 | Hull Hans Chief Business Officer | Award | 19,337 | — | Form 4 |
| Jul 9, 2024 | Cummings Keith Lamont CFO | Award | 21,313 | — | Form 4 |
Cheung Lily
Chief Human Resource Officer
Date
Jan 20
Shares
7,534
Price
$1.28
Value
$10K
Coulie Bernard
President and CEO · Director
Date
Jan 20
Shares
89,375
Price
$1.28
Value
$114K
Cheung Lily
Chief Human Resource Officer
Date
Jan 23
Shares
25,875
Price
—
Value
—
Ouimette Mike
General Counsel & Corp. Sec'y
Date
Jan 23
Shares
35,000
Price
—
Value
—
Coulie Bernard
President and CEO · Director
Date
Jan 23
Shares
162,500
Price
—
Value
—
Coulie Bernard
President and CEO · Director
Date
Jan 17
Shares
52,419
Price
$11.20
Value
$587K
Hull Hans
Chief Business Officer
Date
Jan 17
Shares
15,936
Price
$11.20
Value
$179K
Lefebvre Eric
Chief Medical Officer
Date
Jan 17
Shares
18,478
Price
$11.20
Value
$207K
Cheung Lily
Chief Human Resource Officer
Date
Jan 17
Shares
3,740
Price
$11.20
Value
$42K
Ouimette Mike
General Counsel & Corp. Sec'y
Date
Jan 17
Shares
13,270
Price
$11.20
Value
$149K
Ouimette Mike
General Counsel & Corp. Sec'y
Date
Jan 22
Shares
10,230
Price
$10.99
Value
$112K
Lefebvre Eric
Chief Medical Officer
Date
Jul 10
Shares
12,319
Price
$11.56
Value
$142K
Coulie Bernard
President and CEO · Director
Date
Jul 10
Shares
38,710
Price
$11.56
Value
$447K
Ouimette Mike
General Counsel & Corp. Sec'y
Date
Jul 10
Shares
7,656
Price
$11.56
Value
$89K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PLRX insider trading
PLRX insider trades
Pliant Therapeutics, Inc. (PLRX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Cummings Keith Lamont (CFO), Cheung Lily (Chief Human Resource Officer), Coulie Bernard (President and CEO · Director). Over the past 12 months, 4 insiders have filed transactions with the SEC. PLRX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Pliant Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PLRX insider trading · 5 questionsThe insiders of Pliant Therapeutics, Inc. (PLRX) include executives and directors such as Cummings Keith Lamont (CFO), Cheung Lily (Chief Human Resource Officer), Coulie Bernard (President and CEO · Director), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026